Full-Time

SAP Principal Architect

Transportation Management

Updated on 9/12/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$167.7k - $226.9k/yr

+ Annual bonus + Stock-based long-term incentives

Remote in USA

Remote

Bachelor's, Master's, PhD, Associate's

Category
IT Operations (1)
Required Skills
ERP
Supply Chain Management
SAP Products
Quality Assurance (QA)
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Doctorate degree and 2 years of SAP Transportation Management implementation experience, or a master's degree and 6 years of SAP Transportation Management implementation experience, or a bachelor's degree and 8 years of SAP Transportation Management implementation experience, or an associate's degree and 10 years of SAP Transportation Management implementation experience, or a high school diploma/GED and 12 years of SAP Transportation Management implementation experience.
Responsibilities
  • Help drive the successful design, architecture, build, testing, and implementation of the SAP S/4 Transportation Management solution across Amgen manufacturing and distribution sites.
  • Partner with business leads and business engagement teams to support business cases for the information technology roadmap and business strategy.
  • Collaborate with business, operations information systems, and enterprise resource planning solution architects on cross-functional integrations and end-to-end solution design.
  • Serve as solution owner for SAP Transportation Management solutions within the global enterprise resource planning architecture team.
  • Lead continuous improvements to drive information technology effectiveness with the business and information technology teams.
  • Collaborate with business and operations information systems teams to identify future business needs and prioritize resources and effort for business-critical projects, enhancements, and process improvements.
  • Deliver portfolio investments and ensure business value outcomes are realized based on prioritized business needs.
  • Drive cross-functional initiatives required for regulatory compliance.
  • Use deep business knowledge to drive engagement on major information technology initiatives.
  • Influence architecture decisions and solution choices with business stakeholders and enterprise architects.
  • Manage the implementation vendor and hold it accountable for project scope, service-level agreements, and critical metrics.
  • Drive configuration and development activities to meet business requirements through internal and external teams.
  • Ensure required functional, configuration, and technical design documents for SAP Transportation Management capabilities are created in compliance with GxP requirements and enterprise resource planning architecture standards.
  • Support validation and quality assurance teams in ensuring GxP compliance of SAP Transportation Management capabilities with corporate information technology change-management standards and standard operating procedures, following 21 CFR Part 11 and Annex 11 requirements.
  • Promote adoption of SAP industry best practices within the S/4 Transportation Management and logistics execution workstream.
Desired Qualifications
  • 10 to 15 years of experience in SAP Transportation Management, including at least 3 to 4 end-to-end S/4 Transportation Management implementations.
  • Understanding of SAP supply chain processes.
  • Knowledge of SAP Transportation Management master data, Transportation Requirement Management, transportation planning and execution, charge calculation, and freight settlement.
  • Knowledge of real-time tracking, monitoring, exception handling, and analysis of sales orders, deliveries, shipments, and freight conditions in a production-support environment.
  • Hands-on experience with order-based and delivery-based processes, including selection, planning profiles, condition optimizer planning and scheduling, freight execution carrier selection, tendering, subcontracting, and cost distribution.
  • Understanding of inbound and outbound domestic and international shipments, Transportation Load Builder, full truckload and less-than-truckload transportation, transportation modes, and freight settlement.
  • Experience integrating SAP Transportation Management with SAP Sales and Distribution, Materials Management, Financial Accounting, Event Management, Global Trade Services, Environment Health and Safety, and Extended Warehouse Management.
  • Experience integrating SAP Transportation Management with the Logistics Business Network, freight collaboration, and Global Track and Trace.
  • Experience with carrier onboarding in the Logistics Business Network and Global Track and Trace, and carrier settings.
  • Contribution to the business through innovation ideas and proof-of-concept work.
  • Ability to explain technology solutions in business terms, establish rapport, and persuade others.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.